150 related articles for article (PubMed ID: 37011667)
1. The impacts of menopausal hormone therapy on longer-term health consequences of ovarian hormone deficiency.
Yoon BK
Climacteric; 2023 Jun; 26(3):193-197. PubMed ID: 37011667
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormone therapy and mild cognitive impairment: a randomized, placebo-controlled trial.
Yoon BK; Chin J; Kim JW; Shin MH; Ahn S; Lee DY; Seo SW; Na DL
Menopause; 2018 Aug; 25(8):870-876. PubMed ID: 29846283
[TBL] [Abstract][Full Text] [Related]
3. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.
Khalil RA
Biochem Pharmacol; 2013 Dec; 86(12):1627-42. PubMed ID: 24099797
[TBL] [Abstract][Full Text] [Related]
4. Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial.
Park CW; Lim SJ; Moon YW; Choi SH; Shin MH; Min YK; Yoon BK; Park YS
Climacteric; 2021 Aug; 24(4):408-414. PubMed ID: 34240673
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Menopausal Hormone Therapy on Serum Level of C-reactive Protein in Postmenopausal Korean Women.
Shin W; Kim SE; Lee JY; Seo JW; Hyun HS; Suh JH; Choi D; Yoon BK
J Menopausal Med; 2019 Apr; 25(1):49-54. PubMed ID: 31080789
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy and women's health: An umbrella review.
Zhang GQ; Chen JL; Luo Y; Mathur MB; Anagnostis P; Nurmatov U; Talibov M; Zhang J; Hawrylowicz CM; Lumsden MA; Critchley H; Sheikh A; Lundbäck B; Lässer C; Kankaanranta H; Lee SH; Nwaru BI
PLoS Med; 2021 Aug; 18(8):e1003731. PubMed ID: 34339416
[TBL] [Abstract][Full Text] [Related]
7. Prevention of postmenopausal osteoporosis in Chinese women: a 5-year, double-blind, randomized, parallel placebo-controlled study.
Ran SY; Yu Q; Chen Y; Lin SQ
Climacteric; 2017 Aug; 20(4):391-396. PubMed ID: 28523945
[TBL] [Abstract][Full Text] [Related]
8. Vascular effects of estrogenic menopausal hormone therapy.
Reslan OM; Khalil RA
Rev Recent Clin Trials; 2012 Feb; 7(1):47-70. PubMed ID: 21864249
[TBL] [Abstract][Full Text] [Related]
9. Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.
Masood DE; Roach EC; Beauregard KG; Khalil RA
Curr Drug Metab; 2010 Oct; 11(8):693-714. PubMed ID: 21189141
[TBL] [Abstract][Full Text] [Related]
10. Progesterone for treatment of symptomatic menopausal women.
Prior JC
Climacteric; 2018 Aug; 21(4):358-365. PubMed ID: 29962247
[TBL] [Abstract][Full Text] [Related]
11. Cognitive health after menopause: Does menopausal hormone therapy affect it?
Stute P; Wienges J; Koller AS; Giese C; Wesemüller W; Janka H; Baumgartner S
Best Pract Res Clin Endocrinol Metab; 2021 Dec; 35(6):101565. PubMed ID: 34538724
[TBL] [Abstract][Full Text] [Related]
12. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
L'Hermite M
Climacteric; 2017 Aug; 20(4):331-338. PubMed ID: 28301216
[TBL] [Abstract][Full Text] [Related]
13. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women.
Farr JN; Khosla S; Miyabara Y; Miller VM; Kearns AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):E249-57. PubMed ID: 23322818
[TBL] [Abstract][Full Text] [Related]
14. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study.
Miller VM; Taylor HS; Naftolin F; Manson JE; Gleason CE; Brinton EA; Kling JM; Cedars MI; Dowling NM; Kantarci K; Harman SM
Climacteric; 2021 Apr; 24(2):139-145. PubMed ID: 32880220
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
16. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial.
Casanova G; Spritzer PM
Lipids Health Dis; 2012 Oct; 11():133. PubMed ID: 23046709
[TBL] [Abstract][Full Text] [Related]
17. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Cobin RH; Goodman NF;
Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
[TBL] [Abstract][Full Text] [Related]
18. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
19. [Menopause hormone therapy and cognition. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
André G
Gynecol Obstet Fertil Senol; 2021 May; 49(5):448-454. PubMed ID: 33757928
[TBL] [Abstract][Full Text] [Related]
20. Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study.
Chang WC; Wang JH; Ding DC
Maturitas; 2022 Nov; 165():72-77. PubMed ID: 35933795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
